Total Payments
$669,511
2024 Payments
$104,215
Companies
29
Transactions
531
Medicare Patients
4,942
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$516,220 (77.1%)
Consulting$115,778 (17.3%)
Travel$29,352 (4.4%)
Food & Beverage$6,765 (1.0%)
Research$1,322 (0.2%)
Education$73.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $484,942 | 225 | 72.4% |
| Consulting Fee | $115,778 | 52 | 17.3% |
| Honoraria | $31,278 | 22 | 4.7% |
| Travel and Lodging | $29,352 | 76 | 4.4% |
| Food and Beverage | $6,765 | 148 | 1.0% |
| Unspecified | $1,322 | 7 | 0.2% |
| Education | $73.95 | 1 | 0.0% |
Payments by Type
General
$668,188
524 transactions
Research
$1,322
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $155,520 | 103 | $0 (2024) |
| BeiGene USA, Inc. | $133,806 | 77 | $0 (2024) |
| Lilly USA, LLC | $58,265 | 30 | $0 (2024) |
| Seagen Inc. | $53,176 | 49 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $47,897 | 56 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $33,976 | 37 | $0 (2023) |
| ABBVIE INC. | $30,041 | 30 | $0 (2024) |
| Janssen Biotech, Inc. | $30,027 | 21 | $0 (2023) |
| Celgene Corporation | $28,353 | 15 | $0 (2020) |
| Seattle Genetics, Inc. | $26,053 | 23 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $104,215 | 68 | BeiGene USA, Inc. ($30,996) |
| 2023 | $118,527 | 91 | Lilly USA, LLC ($35,665) |
| 2022 | $131,376 | 87 | Kite Pharma, Inc. ($35,477) |
| 2021 | $119,593 | 79 | BeiGene USA, Inc. ($35,484) |
| 2020 | $100,240 | 85 | Kite Pharma, Inc. ($24,328) |
| 2019 | $57,486 | 57 | Kite Pharma, Inc. ($20,543) |
| 2018 | $30,370 | 41 | Kite Pharma, Inc. ($20,225) |
| 2017 | $7,703 | 23 | Seattle Genetics, Inc. ($6,824) |
All Payment Transactions
531 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: CELLT | ||||||
| 12/16/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $44.63 | General |
| Category: CELLT | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 11/22/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: CELLT | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: CELLT | ||||||
| 09/18/2024 | Kite Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 08/22/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $146.11 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 07/31/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: CELLT | ||||||
| 07/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,375.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $124.01 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 05/30/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Follicular Lymphoma | Regeneron Pharmaceuticals, Inc. | $1,307 | 6 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 936 | 2,186 | $779,483 | $250,316 |
| 2022 | 11 | 1,244 | 2,664 | $647,407 | $219,669 |
| 2021 | 12 | 1,357 | 2,974 | $650,309 | $299,926 |
| 2020 | 13 | 1,405 | 35,300 | $1.0M | $448,382 |
Total Patients
4,942
Total Services
43,124
Medicare Billing
$1.2M
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 267 | 600 | $180,388 | $86,466 | 47.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 339 | 615 | $147,280 | $63,224 | 42.9% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 23 | 360 | $292,752 | $39,699 | 13.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 60 | 293 | $63,240 | $27,919 | 44.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 61 | 61 | $28,092 | $11,522 | 41.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 55 | 73 | $30,796 | $10,524 | 34.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 35 | 48 | $8,476 | $3,200 | 37.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 38 | $5,868 | $2,435 | 41.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $5,970 | $2,224 | 37.3% |
| 38221 | Biopsy of bone marrow | Office | 2023 | 11 | 11 | $6,590 | $1,616 | 24.5% |
| 38220 | Aspiration of bone marrow sample for diagnosis | Office | 2023 | 11 | 11 | $6,070 | $778.58 | 12.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 56 | $3,961 | $705.60 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 232 | 572 | $171,600 | $87,491 | 51.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 286 | 491 | $207,527 | $51,508 | 24.8% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 12 | 192 | $129,060 | $25,165 | 19.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 220 | $44,000 | $18,326 | 41.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 52 | 52 | $25,480 | $9,986 | 39.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 25 | 55 | $8,800 | $8,784 | 99.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 54 | $23,220 | $8,717 | 37.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 326 | 682 | $20,460 | $5,178 | 25.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 29 | 36 | $7,020 | $2,245 | 32.0% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 165 | 263 | $7,890 | $1,673 | 21.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 21 | 47 | $2,350 | $596.20 | 25.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 190 | 424 | $127,200 | $67,482 | 53.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 82 | 413 | $66,080 | $66,181 | 100.2% |
About Dr. Lori Leslie, M.D
Dr. Lori Leslie, M.D is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2009. The National Provider Identifier (NPI) number assigned to this provider is 1972746394.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lori Leslie, M.D has received a total of $669,511 in payments from pharmaceutical and medical device companies, with $104,215 received in 2024. These payments were reported across 531 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($484,942).
As a Medicare-enrolled provider, Leslie has provided services to 4,942 Medicare beneficiaries, totaling 43,124 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 04/15/2009
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1972746394
Products in Payments
- Yescarta (Drug) $139,120
- BRUKINSA (Drug) $132,831
- ADCETRIS (Biological) $70,277
- IMBRUVICA (Drug) $49,840
- CALQUENCE (Drug) $47,508
- Revlimid (Drug) $27,775
- TAZVERIK (Drug) $24,351
- Imbruvica (Drug) $17,606
- Epkinly (Drug) $16,575
- EPKINLY (Drug) $14,147
- JAYPIRCA (Drug) $13,400
- VENCLEXTA (Drug) $12,724
- Tecartus (Drug) $11,530
- SGN35 (Biological) $6,780
- XPOVIO (Drug) $1,966
- UKONIQ (Drug) $1,816
- Adcetris (Biological) $1,072
- clonoSEQ (Device) $896.49
- Istodax (Drug) $578.00
- COPIKTRA (Drug) $146.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884
Dr. David Siegel, Md, MD
Hematology — Payments: $469,559
Hematology $469,559